Clearmind's Hong Kong PTSD patent application is published, not granted
A published application for psychedelic-derived PTSD compounds signals IP positioning, not clinical or regulatory progress. Trial teams should read it that way.
What happened
On 19 November 2026, Clearmind Medicine Inc. said a Hong Kong patent application covering psychedelic-derived compounds for PTSD and other mental health disorders has been published. The company's statement, filed as an exhibit with the US Securities and Exchange Commission, is explicit on one point: no patent has yet been granted.
That qualifier shapes everything else. The records give no details on the compounds, the claims, the filing date or any clinical programme behind the application. They also do not say whether the compound has been tested in people. Those points are not yet known from the material available, and this article does not fill them in.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Sources this analysis is based on
- Clearmind Medicine's psychedelic-derived PTSD compound patent application published in Hong Kong Clearmind Medicine Inc. · Thu 19 Nov 2026
- BfArM lists ArcRoyal field safety notice for procedure trays containing BD Connecta Stopcock BfArM field safety notices · Thu 19 Nov 2026
- Health Canada posts Type II recall of Philips Bridge Prep Kit over guidewire resistance Health Canada · Thu 19 Nov 2026
- Olympus updates reprocessing instructions for GF-UC140P-AL5 endoscopic ultrasound gastrovideoscopes in Canada Health Canada · Thu 19 Nov 2026
- Teleflex recalls PICC kits and spring-wire guides over coating detachment risk, Health Canada reports Health Canada · Wed 18 Nov 2026
- Health Canada: Raz Design recalls shower commode chairs over seats that can break Health Canada · Wed 18 Nov 2026
Written by VigiEye's editorial system with AI assistance (model claude-sonnet-5-5) strictly from the official records listed above. It can contain errors: check the sources before acting. Not legal, medical or investment advice.
Safety judgment belongs apart from the product line, and CBER just said so
FDA's new CBER Safety Council sits outside the product offices. PV leaders should test whether their own safety decisions have the same structural distance from commercial pressure.
Definitions decide pathways: UK gene therapy rewrite means check your category now
The UK will widen its gene therapy definition to catch synthetic and genome-editing products. Regulatory teams should test their pipelines against the new boundary before the legislation arrives.
EMA's CMV immunoglobulin PSUSA ends in maintenance: what a quiet outcome tells PV teams
EMA has closed its periodic safety review of cytomegalovirus immunoglobulin with the marketing authorisations maintained. What the outcome does and does not tell MAHs is worth spelling out.